Our portfolio companies benefit from experienced management, scientists, consultants and investors from all over the world.

The Ascend portfolio today consists of the following companies/projects in preclinical and clinical development:

Otologic Pharmaceutics: Developing therapeutic solutions for hearing health.

  • Auditus:  a clinical stage asset designed to reduce acute acoustic trauma.  This asset is licensed to Oblato.
  • Autigen: a preclinical program focused on regrowing the sensory hairs cells within the cochlear. The is a joint collaboration with Boehringer Ingelheim

Azorilla: Innovative chemistry designed to neutralize and eliminate noxious chemical compounds with applications ranging from consumer products to industrial manufacturing.

Algeron: Clostridium difficile vaccine that could protect against multiple hypervirulent strains of Cdiff and could effectively prevent relapse.

Cadenza Bio:  Focused on development of novel therapeutic drugs for treatment of demyelinating, inflammatory, and neurodegenerative diseases with a secondary program in endometriosis.

Previous Portfolio companies: Kirrhos Pharmaceuticals-developing a small molecule for nonalcoholic steatohepatitis (NASH).